nodes	percent_of_prediction	percent_of_DWPC	metapath
Pralidoxime—BCHE—peripheral nervous system neoplasm	0.856	1	CbGaD
Pralidoxime—BCHE—Cisplatin—peripheral nervous system neoplasm	0.0458	1	CbGbCtD
Pralidoxime—Muscle necrosis—Melphalan—peripheral nervous system neoplasm	0.0424	0.432	CcSEcCtD
Pralidoxime—Inflammation—Tretinoin—peripheral nervous system neoplasm	0.00212	0.0216	CcSEcCtD
Pralidoxime—Inflammation—Isotretinoin—peripheral nervous system neoplasm	0.00212	0.0216	CcSEcCtD
Pralidoxime—Inflammation—Alitretinoin—peripheral nervous system neoplasm	0.00161	0.0164	CcSEcCtD
Pralidoxime—Inflammation—Etoposide—peripheral nervous system neoplasm	0.00125	0.0128	CcSEcCtD
Pralidoxime—Drowsiness—Tretinoin—peripheral nervous system neoplasm	0.00115	0.0117	CcSEcCtD
Pralidoxime—Drowsiness—Isotretinoin—peripheral nervous system neoplasm	0.00115	0.0117	CcSEcCtD
Pralidoxime—Haemoglobin—Topotecan—peripheral nervous system neoplasm	0.00105	0.0107	CcSEcCtD
Pralidoxime—Haemorrhage—Topotecan—peripheral nervous system neoplasm	0.00104	0.0106	CcSEcCtD
Pralidoxime—Haemoglobin—Isotretinoin—peripheral nervous system neoplasm	0.00104	0.0106	CcSEcCtD
Pralidoxime—Haemoglobin—Tretinoin—peripheral nervous system neoplasm	0.00104	0.0106	CcSEcCtD
Pralidoxime—Haemorrhage—Tretinoin—peripheral nervous system neoplasm	0.00103	0.0105	CcSEcCtD
Pralidoxime—Haemorrhage—Isotretinoin—peripheral nervous system neoplasm	0.00103	0.0105	CcSEcCtD
Pralidoxime—Haemoglobin—Melphalan—peripheral nervous system neoplasm	0.00102	0.0104	CcSEcCtD
Pralidoxime—Haemorrhage—Melphalan—peripheral nervous system neoplasm	0.00102	0.0104	CcSEcCtD
Pralidoxime—Hyperventilation—Epirubicin—peripheral nervous system neoplasm	0.00099	0.0101	CcSEcCtD
Pralidoxime—Muscular weakness—Vincristine—peripheral nervous system neoplasm	0.000961	0.00979	CcSEcCtD
Pralidoxime—Hyperventilation—Doxorubicin—peripheral nervous system neoplasm	0.000916	0.00934	CcSEcCtD
Pralidoxime—Drowsiness—Alitretinoin—peripheral nervous system neoplasm	0.000871	0.00888	CcSEcCtD
Pralidoxime—Vision blurred—Tretinoin—peripheral nervous system neoplasm	0.000847	0.00863	CcSEcCtD
Pralidoxime—Vision blurred—Isotretinoin—peripheral nervous system neoplasm	0.000847	0.00863	CcSEcCtD
Pralidoxime—Agitation—Isotretinoin—peripheral nervous system neoplasm	0.000826	0.00842	CcSEcCtD
Pralidoxime—Agitation—Tretinoin—peripheral nervous system neoplasm	0.000826	0.00842	CcSEcCtD
Pralidoxime—Haemoglobin—Alitretinoin—peripheral nervous system neoplasm	0.000786	0.00801	CcSEcCtD
Pralidoxime—Haemorrhage—Alitretinoin—peripheral nervous system neoplasm	0.000782	0.00797	CcSEcCtD
Pralidoxime—Tachycardia—Tretinoin—peripheral nervous system neoplasm	0.000716	0.00729	CcSEcCtD
Pralidoxime—Tachycardia—Isotretinoin—peripheral nervous system neoplasm	0.000716	0.00729	CcSEcCtD
Pralidoxime—Tachycardia—Melphalan—peripheral nervous system neoplasm	0.000707	0.0072	CcSEcCtD
Pralidoxime—Inflammation—Epirubicin—peripheral nervous system neoplasm	0.000703	0.00716	CcSEcCtD
Pralidoxime—Somnolence—Tretinoin—peripheral nervous system neoplasm	0.000652	0.00664	CcSEcCtD
Pralidoxime—Somnolence—Isotretinoin—peripheral nervous system neoplasm	0.000652	0.00664	CcSEcCtD
Pralidoxime—Inflammation—Doxorubicin—peripheral nervous system neoplasm	0.00065	0.00663	CcSEcCtD
Pralidoxime—Vision blurred—Alitretinoin—peripheral nervous system neoplasm	0.000642	0.00654	CcSEcCtD
Pralidoxime—Pain—Topotecan—peripheral nervous system neoplasm	0.000632	0.00644	CcSEcCtD
Pralidoxime—Pain—Isotretinoin—peripheral nervous system neoplasm	0.000627	0.00639	CcSEcCtD
Pralidoxime—Pain—Tretinoin—peripheral nervous system neoplasm	0.000627	0.00639	CcSEcCtD
Pralidoxime—Agitation—Alitretinoin—peripheral nervous system neoplasm	0.000626	0.00638	CcSEcCtD
Pralidoxime—Pain—Melphalan—peripheral nervous system neoplasm	0.000619	0.00631	CcSEcCtD
Pralidoxime—Agitation—Vincristine—peripheral nervous system neoplasm	0.000603	0.00615	CcSEcCtD
Pralidoxime—Vision blurred—Cisplatin—peripheral nervous system neoplasm	0.000547	0.00557	CcSEcCtD
Pralidoxime—Tachycardia—Alitretinoin—peripheral nervous system neoplasm	0.000542	0.00553	CcSEcCtD
Pralidoxime—Pain—Dactinomycin—peripheral nervous system neoplasm	0.000513	0.00522	CcSEcCtD
Pralidoxime—Diplopia—Epirubicin—peripheral nervous system neoplasm	0.000495	0.00504	CcSEcCtD
Pralidoxime—Somnolence—Alitretinoin—peripheral nervous system neoplasm	0.000494	0.00504	CcSEcCtD
Pralidoxime—Dizziness—Topotecan—peripheral nervous system neoplasm	0.000489	0.00498	CcSEcCtD
Pralidoxime—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.000485	0.00494	CcSEcCtD
Pralidoxime—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.000485	0.00494	CcSEcCtD
Pralidoxime—Pain—Alitretinoin—peripheral nervous system neoplasm	0.000475	0.00484	CcSEcCtD
Pralidoxime—Headache—Topotecan—peripheral nervous system neoplasm	0.000463	0.00472	CcSEcCtD
Pralidoxime—Tachycardia—Cisplatin—peripheral nervous system neoplasm	0.000462	0.00471	CcSEcCtD
Pralidoxime—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000459	0.00468	CcSEcCtD
Pralidoxime—Headache—Tretinoin—peripheral nervous system neoplasm	0.000459	0.00468	CcSEcCtD
Pralidoxime—Pain—Vincristine—peripheral nervous system neoplasm	0.000458	0.00467	CcSEcCtD
Pralidoxime—Diplopia—Doxorubicin—peripheral nervous system neoplasm	0.000458	0.00467	CcSEcCtD
Pralidoxime—Nausea—Topotecan—peripheral nervous system neoplasm	0.000439	0.00448	CcSEcCtD
Pralidoxime—Muscular weakness—Epirubicin—peripheral nervous system neoplasm	0.000436	0.00445	CcSEcCtD
Pralidoxime—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000436	0.00444	CcSEcCtD
Pralidoxime—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000436	0.00444	CcSEcCtD
Pralidoxime—Nausea—Melphalan—peripheral nervous system neoplasm	0.00043	0.00438	CcSEcCtD
Pralidoxime—Tachycardia—Etoposide—peripheral nervous system neoplasm	0.000423	0.00432	CcSEcCtD
Pralidoxime—Pain—Cisplatin—peripheral nervous system neoplasm	0.000405	0.00413	CcSEcCtD
Pralidoxime—Muscular weakness—Doxorubicin—peripheral nervous system neoplasm	0.000404	0.00412	CcSEcCtD
Pralidoxime—Somnolence—Etoposide—peripheral nervous system neoplasm	0.000386	0.00393	CcSEcCtD
Pralidoxime—Drowsiness—Epirubicin—peripheral nervous system neoplasm	0.000381	0.00389	CcSEcCtD
Pralidoxime—Pain—Etoposide—peripheral nervous system neoplasm	0.000371	0.00378	CcSEcCtD
Pralidoxime—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000368	0.00375	CcSEcCtD
Pralidoxime—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000356	0.00363	CcSEcCtD
Pralidoxime—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000354	0.00361	CcSEcCtD
Pralidoxime—Drowsiness—Doxorubicin—peripheral nervous system neoplasm	0.000353	0.0036	CcSEcCtD
Pralidoxime—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000348	0.00355	CcSEcCtD
Pralidoxime—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	0.000344	0.00351	CcSEcCtD
Pralidoxime—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	0.000342	0.00349	CcSEcCtD
Pralidoxime—Headache—Vincristine—peripheral nervous system neoplasm	0.000336	0.00342	CcSEcCtD
Pralidoxime—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.00033	0.00336	CcSEcCtD
Pralidoxime—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	0.000318	0.00324	CcSEcCtD
Pralidoxime—Nausea—Vincristine—peripheral nervous system neoplasm	0.000318	0.00324	CcSEcCtD
Pralidoxime—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	0.000317	0.00323	CcSEcCtD
Pralidoxime—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000287	0.00292	CcSEcCtD
Pralidoxime—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000281	0.00287	CcSEcCtD
Pralidoxime—Vision blurred—Epirubicin—peripheral nervous system neoplasm	0.000281	0.00286	CcSEcCtD
Pralidoxime—Agitation—Epirubicin—peripheral nervous system neoplasm	0.000274	0.00279	CcSEcCtD
Pralidoxime—Headache—Etoposide—peripheral nervous system neoplasm	0.000272	0.00277	CcSEcCtD
Pralidoxime—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	0.00026	0.00265	CcSEcCtD
Pralidoxime—Nausea—Etoposide—peripheral nervous system neoplasm	0.000258	0.00263	CcSEcCtD
Pralidoxime—Agitation—Doxorubicin—peripheral nervous system neoplasm	0.000253	0.00258	CcSEcCtD
Pralidoxime—Tachycardia—Epirubicin—peripheral nervous system neoplasm	0.000237	0.00242	CcSEcCtD
Pralidoxime—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.00022	0.00224	CcSEcCtD
Pralidoxime—Somnolence—Epirubicin—peripheral nervous system neoplasm	0.000216	0.0022	CcSEcCtD
Pralidoxime—Pain—Epirubicin—peripheral nervous system neoplasm	0.000208	0.00212	CcSEcCtD
Pralidoxime—Somnolence—Doxorubicin—peripheral nervous system neoplasm	0.0002	0.00204	CcSEcCtD
Pralidoxime—Pain—Doxorubicin—peripheral nervous system neoplasm	0.000192	0.00196	CcSEcCtD
Pralidoxime—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000161	0.00164	CcSEcCtD
Pralidoxime—Headache—Epirubicin—peripheral nervous system neoplasm	0.000152	0.00155	CcSEcCtD
Pralidoxime—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.000149	0.00152	CcSEcCtD
Pralidoxime—Nausea—Epirubicin—peripheral nervous system neoplasm	0.000144	0.00147	CcSEcCtD
Pralidoxime—Headache—Doxorubicin—peripheral nervous system neoplasm	0.000141	0.00144	CcSEcCtD
Pralidoxime—Nausea—Doxorubicin—peripheral nervous system neoplasm	0.000134	0.00136	CcSEcCtD
